IL6 and COVID-19: These cases are notably felt to be IL-6 driven, responding to the anti-IL-6 drug tocilizumab.13 IL-6 plasma levels are unfavourable prognosticators in COVID-19, therefore there is potential that ICB may lead to more severe immune hyperactivation or increased incidence of ARDS in COVID-19 patients.